Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2025-04-16 Annual Report
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Annual Report 2025
Annual Report
2025-04-16 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as a Definitive Additional Materials filing related to proxy solicitation. Proxy Statements and related materials are used to provide information to shareholders and solicit their votes for meetings. Therefore, this document fits the category of Proxy Solicitation & Information Statement filings.
2025-04-15 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-04-15 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Enveric Biosciences, Inc. dated April 14, 2025. It reports a change in the company's independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. It includes detailed disclosures about the change, the absence of disagreements or reportable events with the former auditor, and references to the audit reports for fiscal years ended December 31, 2023 and 2024. The document also attaches a letter from the former auditor to the SEC. This type of filing is a current report on a significant event (change in auditor) and is not a full annual report, audit report, or other financial statement. It is a regulatory filing reporting a material event as required by the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7679 characters) and content confirm it is not merely an announcement but a detailed regulatory disclosure, yet it does not contain full financial statements or management discussion. Confidence is high due to the clear identification of the form and content.
2025-04-14 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 100% confidence The document is a Form S-3/A registration statement amendment filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933, used for registering securities offerings. The text includes details about the securities to be offered, the registration process, and disclaimers typical of a prospectus and registration statement. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities issuance and fundraising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive filing about securities registration and offering.
2025-04-10 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the 2025 Annual Meeting of Stockholders of Enveric Biosciences, Inc. It includes detailed information about the meeting agenda, proposals to be voted on (election of directors, say-on-pay, reverse stock split, auditor ratification, adjournment), instructions for voting, and other governance-related disclosures. The document is not an annual report, earnings release, or financial report but is specifically a proxy solicitation document sent to shareholders to inform them and solicit votes for the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2025-04-04 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.